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Background: At least one million people are infected with human T-lymphotropic virus type 1 (HTLV-1) in Japan, a
small percentage of whom develop HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) or adult
T-cell leukemia/lymphoma (ATLL). Patients with HAM/TSP suffer from progressively worsening myelopathic
symptoms, such as motor disability and bladder dysfunction, and may become wheelchair-bound or even
bedridden.
Methods: To learn more about this rare, debilitating disease, we established the national registration system
“HAM-net” in March 2012. We continuously obtain detailed data from enrolled patients using the registration forms
and an annual telephone interview. In this retrospective study, we describe the demographics and clinical histories
of 383 registered patients from all over Japan.
Results: Patients were diagnosed at a median of 53 years old, long after disease onset at 45. Most (55.3 %) were
originally from the southernmost regions, Kyushu and Okinawa. The main initial symptoms were difficulty walking
(81.9 %), urinary dysfunction (38.5 %), and lower limb sensory disturbances (13.9 %). Many patients reported
frequent leg numbness and leg pain, and the vast majority required medical intervention for urinary symptoms and
constipation. A median of 8 years elapsed from the onset of motor symptoms to Osame Motor Disability Score
(OMDS) 5 (requiring unilateral support), 12.5 years to OMDS 6 (requiring bilateral support), and 18 years to OMDS 9
(unable to walk). Health Assessment Questionnaire - Disability Index (HAQ-DI) tasks related to mobility, as opposed
to hand motions, were very difficult for HAM/TSP patients and well-correlated with OMDS. Scores on the MOS
36-Item Short-Form Health Survey (SF-36) indicated that physical functioning was severely impaired in HAM/TSP
patients. Patients with a history of blood transfusion (19.1 %) were older and suffered from more severe disability as
indicated by their high HAQ-DI scores. Patients with a family history of HAM/TSP (8.4 %) were younger and had
relatively mild symptoms given their long disease durations; many (15.6 %) also had a relative with ATLL.
Conclusions: The HAM-net national registration system has been an effective tool for gathering personal and
clinical data from HAM/TSP patients scattered throughout Japan. We expect to conduct many retrospective and
prospective epidemiological studies using HAM-net in the future.
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Human T-lymphotropic virus type 1 (HTLV-1) is a
retrovirus mainly endemic to southwestern Japan, South
America, sub-Saharan Africa, and the Caribbean islands.
A recent report on global HTLV-1 epidemiology gave an
estimate of only five to ten million HTLV-1-infected in-
dividuals worldwide [1]. However, the results were based
only on endemic areas with reliable data, suggesting that
the actual number may be much higher if countries such
as China and India were also included. At least one mil-
lion are estimated to reside in Japan [2], with prevalence
rates differing widely among prefectures, ranging from
less than 1 % in the north to more than 6 % in the south,
where in certain towns as many as 30–40 % of adults
aged 50 and over are infected [1]. While the vast major-
ity of those infected remain lifelong asymptomatic car-
riers, 0.25–3 % develop HTLV-1-associated myelopathy/
tropical spastic paraparesis (HAM/TSP) [3–5], 2–7 %
develop adult T-cell leukemia/lymphoma (ATLL) [6–8],
and some develop other inflammatory conditions such
as uveitis, dermatitis, thyroiditis, pneumonitis, myositis,
and arthritis [9].
Patients with HAM/TSP suffer from chronic spinal
cord inflammation, experiencing progressively worsening
myelopathic symptoms such as spastic paraparesis, lower
limb sensory disturbances, and bladder and bowel dys-
function [10]. The disease severely impacts their quality
of life, both physically and emotionally, mainly due to
difficulties with locomotion, bladder management, and
chronic pain [11, 12]. In the later stages of the disease,
patients may become wheelchair-bound or even bedrid-
den [13]. Therapies such as corticosteroids and inter-
ferons, which can tame the hyperactive immune
response associated with HAM/TSP, reportedly produce
modest benefits; however, long-term treatment is diffi-
cult to tolerate due to adverse effects that often rival the
symptoms of the disease [14]. Moreover, due in part to
the fact that patients with this rare disease are few and
far between, there have been no proper placebo-
controlled trials for interferons or for corticosteroids.
Thus, the prognosis for HAM/TSP patients is very poor.
In order to gain a clear understanding of the disease
and its impact, it is necessary to learn more about
HAM/TSP, including the frequency and severity of the
symptoms, the speed of disease progression, and the
attributes of the individuals suffering from the disease.
Because HAM/TSP is such a rare disease, it is difficult
to gather a cohort large enough for meaningful epi-
demiological analysis. Therefore, we have established a
national registration system for HAM/TSP patients in
Japan, known as “HAM-net” (Fig. 1). With this system
in place, we can gather data from hundreds of HAM/
TSP patients scattered all throughout Japan, including
personal, demographic, and especially clinical data.There have been other studies describing the character-
istics of patients with HAM/TSP in Japan [15–17] and
elsewhere, such as in the UK [18], Martinique [19],
Brazil [20, 21], Peru [22], and Iran [23], but no patient
registries.
The unique design of HAM-net allows patients from
all over the country to self-report their status in great
detail at yearly intervals, allowing us to obtain volumes
of both retrospective and prospective data. Since there is
no standard protocol for monitoring HAM/TSP symp-
toms, we included several established scales and surveys
in our patient interviews so that we may assess their ap-
plicability to HAM/TSP. HAM-net is flexible enough to
evolve with new findings by adding or subtracting ques-
tions from the yearly interview if indicated. The HAM-
net network is also a valuable resource for recruiting
subjects for clinical studies. Moreover, enrolled patients
benefit by regularly receiving information from our of-
fice, such as updates on our group’s activities and the
progress of HAM/TSP research as well as useful re-
sources. Our satisfaction surveys indicate that enrolled
patients find our newsletters particularly helpful and de-
sire frequent updates [24].
In this paper, we describe the establishment of the
HAM-net patient registry and the first findings made
using this system. These findings constitute the results
of a retrospective epidemiological study in which data
obtained from patients during the registration process
and initial interview were evaluated to establish a de-
tailed profile of patients with HAM/TSP in Japan. In
addition, analysis was performed to investigate how fac-
tors such as history of blood transfusion and family his-
tory of HAM/TSP may correlate with disease severity;
such results could yield insights into how the mode of




The aims of this report are to introduce HAM-net, a
novel HAM/TSP patient registration system, and an-
nounce the first findings produced using this system.
HAM-net is intended to function primarily as a na-
tional database for patient information in order to
determine: the profile of the Japanese HAM/TSP pa-
tient, the most effective methods for monitoring patient
symptoms, and factors that affect disease progression.
In the long-term, these findings will be used to help
physicians more effectively diagnose HAM/TSP, moni-
tor disease progression, and make patient-specific pre-
dictions on disease prognosis, ultimately improving the
HAM/TSP treatment paradigm. Secondary purposes of
HAM-net include establishing a contact database to
recruit patients for clinical studies, raising awareness
Fig. 1 Enrollment process for the HAM-net registration system. This figure is displayed on the English version of the HAM-net website, hamtsp-net.com.
The patient (right) must request a registration packet and mail the completed paperwork to the HAM-net offices, including documentation of the
HAM/TSP diagnosis and a signed informed consent document. HAM-net staff (left) then contact the patient by telephone to conduct an interview every
year. Data is obtained from both the registration documents and the telephone interviews. In return, patients are kept informed with regular newsletters
and updates to the HAM-net website
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tients well informed.
Establishment
The HAM-net national registration system for HAM/
TSP patients was established in March 2012 at the St.
Marianna University School of Medicine in Kanagawa,
Japan, where it is managed by the HAM/TSP research
group in the Department of Rare Diseases Research. The
management team includes scientists, physicians, nurses,
professional clinical research coordinators, professional
data managers and analysts, web administrators, and
secretarial staff. The management team meets once per
month to discuss progress and future directions. Collab-
orators include physicians from other institutions and
HAM/TSP patient groups. This study is approved by the
St. Marianna University School of Medicine Bioethics
Committee (Approval ID No. 2044) and supported by the
Practical Research Project for Rare/Intractable Diseases
from the Japan Agency for Medical Research and Devel-
opment (AMED).
Patient recruitment
Patients diagnosed with HAM/TSP are recruited from
all over Japan by ensuring that informational leaflets are
distributed to patients at clinics, meetings of patient
groups, and lectures. Using the Japanese Society of
Neurology contact list, we sent information about
HAM-net and a copy of the leaflet to all of the roughly
5000 board-certified neurologists in Japan. In addition,
we asked the leader of the national HAM/TSP patient
association to send the leaflets to all members of the
group, which included roughly 300 patients. Information
is also freely available online at the registry website,
hamtsp-net.com.
Patient registration
Patients wishing to register may apply to do so via tele-
phone, FAX, or e-mail. The applicant then receives apacket of registration materials in the mail, including de-
tailed explanations of the research objectives and risks of
enrolling in the study, consent forms, and registration
forms to be filled out by the applicant as well as by the
attending physician, when possible (Fig. 1). The inclu-
sion criteria for HAM-net are confirmed HAM/TSP
diagnosis and informed consent, and there are no exclu-
sion criteria. Once both informed consent and confirm-
ation of diagnosis have been obtained, the applicant may
be enrolled as a subject in the study. The subject may
subsequently withdraw their consent and would be re-
moved from the registry immediately upon request. Pa-
tients were informed that refusal to participate in the
study would not affect their medical care. All subjects in
this study willingly gave written informed consent.
Data collection
Data is collected from registered patients using the
registration forms followed by an in-depth telephone
interview. The nurse or clinical research coordinator
conducting the interview assesses the patient’s health
and quality of life using various scales and surveys over
the course of 45–60 min. The interviewers are instructed
by the principal investigator and provided with a
standard operating procedures manual such that the in-
terviews are conducted in a uniform manner. This tele-
phone interview is conducted once upon registration
and once per year thereafter in order to observe each pa-
tient’s progress over time.
Data storage
All patient information sent to our HAM-net Patient
Registration Center is processed by the Personal Infor-
mation Manager, who de-identifies the data by assigning
each patient an anonymous ID number. The Personal
Information Manager uses a single computer set aside
and designated for this purpose only. Only this de-
identified information is used for data analysis, and
no identifying information will be published. The
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and key.
Data contents
What follows is a brief overview of the types of data
collected from patients:
1. Basic Information (Name, Birthdate, Gender,
Residence).
2. Contact Information.
3. Personal and Financial Information (Occupation,
Income, Employment Status, Marital Status, Family
Structure, Welfare Status, Insurance Status,
Disability Status).
4. Medical Records (Disease History, Treatment
History, Complications, History of Blood
Transfusions, Family History, Blood and
Cerebrospinal Fluid Test Results – when
obtainable from attending physician).
5. Scales and Surveys.
a. Osame Motor Disability Score (OMDS) – Score
ranges from 0 to 13, where 0 indicates no motor
disability and higher scores indicate increasingly
severe motor disability [25]. See Table 2 for
details.
b. Health Assessment Questionnaire – Disability
Index (HAQ-DI)* – Scores range from 0 to 3 for
each of 20 items (overall HAQ score is the
average of these 20 scores), with higher scores
indicating more severe disability in performing
daily tasks [26].
c. Insituto de Pesquisa Clinica Evandro Chagas
Disability Score (IPEC)-1 – Total score ranges
from 0 to 29, with 17 possible points for motor
score, 3 for spasticity score, 4 for sensory score,
and 5 for sphincter score, with more points
indicating more severe neurological disability
[27, 28]. Here we report only on the gait
disturbance subsection of the motor score, which
ranges from 0 to 11, and on the contents of the
sensory section, which describes lower limb pain
and numbness.
d. International Consultation on Incontinence
Questionnaire – Short Form (ICIQ-SF) – Scores
range from 0 to 5, 6 (even numbers only), and 10
for urinary leak frequency, amount, and impact
on daily life, respectively (total ICIQ-SF ranges 0-
21), with higher scores indicating more severe
incontinence [29]. There is also one unscored
qualitative question on leakage circumstances.
e. International Prostate Symptom Score (I-PSS) –
Scores range from 0 to 5 each for incomplete
emptying, frequency, intermittency, urgency,
weak stream, and straining (total I-PSS ranges0–30), with higher scores indicating more severe
symptoms [30].
f. Overactive Bladder Symptom Score (OABSS) –
Scores range from 0 to 2, 3, 5, and 5 for daytime
urinary frequency, nighttime frequency, urgency,
and urgency incontinence, respectively (total
OABSS ranges 0–15), with higher scores
indicating more severe symptoms [31, 32].
g. Nocturia Quality of Life (N-QOL) – Scores range
from 0 to 4 for each of 12 items concerning the
impact of nocturia on quality of life; these scores
are summed and transformed into a standardized
scale from 0 to 100, with higher scores indicating
better quality of life [33]. In addition, there is one
global QOL item asked but not included in the
N-QOL total score.
h. MOS 36-Item Short-Form Health Survey (SF-36) –
The average score for Japanese people was set at 50
with 10 as the standard deviation, with higher
scores indicating better health-related quality of life
[34]. The eight categories assessed were: physical
functioning, role-physical, bodily pain, general
health, vitality, social functioning, role-emotional,
and mental health.Statistical analysis
All analyses were descriptive and exploratory. Although
p values were reported, no significance levels were set
for inference, and all interpretations were descriptive.
All reported p values were two-sided and unadjusted for
multiplicity. Continuous and discrete variables were
summarized using medians with interquartile ranges
(IQR) or numbers of patients with percentages of total
patients, respectively. Differences in continuous and
discrete variables between two groups were assessed
using the Mann-Whitney U test and the Chi-squared
test, respectively. Correlations of two continuous vari-
ables were assessed using the non-parametric Spear-
man’s method. Calculations were made using IBM SPSS
Statistics Version 22.0 software.
Results
Between March 2012 and March 2015, 515 individuals
requested application materials for the HAM-net patient
registration system, and 383 confirmed HAM/TSP pa-
tients proceeded through final registration and com-
pleted the initial interview (Fig. 2). Table 1 summarizes
the results of these interviews.
Demographics
Enrolled patients were a median (IQR) of 63 (56–69)
years old at the time of registration and had been suffer-
ing from the disease for 17 (8–26) years (Fig. 3). The age
of onset varied from 10 to 85 years old, with patients
Fig. 2 Registration and interview timeline for the HAM-net subjects analyzed in this study. Each colored column represents a group of patients
who registered during the same year: 2012 (green), 2013 (blue), or 2014 (purple). Patients who registered in 2015 or later (not shown) were not
included as subjects in this study. All subjects were interviewed once upon registration and then once per year thereafter; however, data from
these follow-up interviews (shown in gray text) are not included in this paper. In total, data from three years of initial interviews for 383 subjects
were analyzed in this retrospective study. A red dotted line separates the data that were and were not analyzed
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40s (23.1 %) and 50s (22.3 %). While the age of onset
was 45 (32–56) years, the age at diagnosis was much
later, at 53 (42–62) years of age. It took 5 (1–12) years
from disease onset to diagnose HAM/TSP in Japan.
Nearly three-quarters (74.2 %) of the patients were
women, and there were no remarkable differences in
age, age of onset, or age at diagnosis between men and
women (data not shown).
HTLV-1 is most prevalent in the southernmost islands,
Kyushu and the Okinawa archipelago, and the eight pre-
fectures composing those islands are considered en-
demic regions [1]. Most (212, 55.3 %) HAM/TSP
patients enrolled in this study were originally from those
regions, even if some (42) had since moved elsewhere.
As shown in Fig. 4, enrolled patients resided in 41 of the
47 prefectures, illustrating how HTLV-1 has spread
throughout Japan. The patient population spiked in the
major metropolitan centers Tokyo (20, 5.2 %) and Osaka
(24, 6.3 %), even though they are not located in the
south. By contrast, Kyoto, a prefecture neighboring
Osaka, was home to only 1 % of the enrolled patients.
It should be noted that our research is based in
Kanagawa prefecture, resulting in a disproportionately
high number of patients (34, 8.9 %) being recruited in
that area. Only 13 patients (3.4 %) were originally
from Kanagawa.
Symptoms
Patients with HAM/TSP are plagued with a variety of
neurological symptoms, notably lower limb pain and
sensory disturbances, urinary and bowel dysfunction,
and motor disability. Impaired mobility can be measured
using OMDS, a motor disability scale ranging fromnormal mobility at OMDS 0 up to complete paraplegia
at OMDS 13 (Table 2) [25]. According to this study, the
majority of HAM/TSP patients in Japan require some
form of support to walk, most commonly a cane, but
can still walk at least 10 m at a time with that support
(OMDS 4–6, 63.0 % of patients). While 28.1 % of pa-
tients were more severely disabled (at or above OMDS
7), fewer than 5.0 % were bedridden (at or above OMDS
11). HAM-net subjects scored a median of 4.0 (3.0–8.0)
out of 11.0 on the gait subsection of the IPEC-1 scale,
which was designed to measure the presence of neuro-
logical symptoms in HAM/TSP patients [27]. Extracting
sensory data from IPEC-1 revealed that leg numbness
and pain heavily impact HAM/TSP patients: the major-
ity of HAM-net subjects reported experiencing leg
numbness, with 184 (48.2 %) indicating that the numb-
ness occurred very often or always; roughly half of the
patients had chronic leg pain, with 89 (23.3 %) reporting
that they were very often or always in pain.
Urinary dysfunction and constipation were also widely
reported among HAM/TSP patients, most of whom
have taken steps to alleviate these troubling symptoms.
At the time of this survey, as many as 234 (61.3 %) pa-
tients suffered from urinary symptoms and 256 (67.0 %)
from constipation, many of whom were using medica-
tion to suppress their symptoms. In addition, several pa-
tients were forced to take more extreme measures: 108
(28.3 %) patients inserted catheters in order to urinate,
and 33 (8.6 %) underwent enemas. There were no no-
ticeable differences regarding how men versus women
managed their symptoms. As shown in Table 1, scores
on the scales and surveys specifically assessing urinary
symptoms (ICIQ-SF, I-PSS, OABSS, and N-QOL) were
varied.
Table 1 Clinical attributes of the HAM/TSP patients enrolled in this study (n = 383)
Time-Points (Years) Median (IQR)
Age at Onset 45 (32 – 56)
Age at Diagnosis 53 (42 – 62)
Age (at Presenta) 63 (56 – 69)
Diagnosis Delay (Time from Onset to Diagnosis) 5 (1 – 12)
Disease Duration (Time from Onset to Presenta) 17 (8 – 26)
Scales/Surveys (Scores) Median (IQR)
OMDS (Range: 0 – 13) 5.0 (5.0 – 7.0)
IPEC-1 Gait Subsection (Range: 0 – 11) 4.0 (3.0 – 8.0)
ICIQ-SF (Range: 0 – 21) 6.0 (0.0 – 11.0)
I-PSS (Range: 0 – 30) 14.5 (6.0 – 22.0)
OABSS (Range: 0 – 15) 6.0 (2.3 – 10.0)
N-QOL (Range: 0 – 100) 91.7 (74.5 – 100.0)
HAQ-DI (Range: 0 – 3) 1.1 (0.8 – 1.6)
SF-36 Physical Functioning (National Average ± SD: 50 ± 10)b -3.5 (-10.7 – 14.5)
SF-36 General Health (National Average ± SD: 50 ± 10)b 38.9 (32.5 – 45.8)
Inquiries Responses Subjects (Percentage)
Sex: Female 284 (74.2 %)
Male 99 (25.8 %)
Initial Symptoms (inclusive): Gait Disturbance 313 (81.9 %)
Urinary Disturbance 147 (38.5 %)
Sensory Disturbance (in legs) 53 (13.9 %)
Other 115 (30.0 %)
History of Blood Transfusion: Yes (Total) 73 (19.1 %)
Yes, Pre-1986 57 (14.9 %)
Unknown 3 (0.8 %)
Urinary Dysfunction: No Symptoms 29 (7.6 %)
Symptoms or Using Medication 234 (61.3 %)
Using Catheters 108 (28.3 %)
Other Management Strategy 11 (2.9 %)
Bowel Dysfunction: No Symptoms 87 (22.8 %)
Symptoms or Using Medication 256 (67.0 %)
Using Enemas 33 (8.6 %)
Other Management Strategy 6 (1.6 %)
Leg Numbness: None 125 (32.7 %)
Occasional 73 (19.1 %)
Severe 184 (48.2 %)
Leg Pain: None 215 (56.3 %)
Occasional 78 (20.4 %)
Severe 89 (23.3 %)
Data are summarized using the median and interquartile range (IQR) or the number of subjects and the percentage of total subjects (%). The full names of the scales
and surveys shown are as follows: Osame Motor Disability Score (OMDS), Health Assessment Questionnaire – Disability Index (HAQ-DI), Insituto de Pesquisa Clinica
Evandro Chagas Disability Score (IPEC)-1, International Consultation on Incontinence Questionnaire – Short Form (ICIQ-SF), International Prostate Symptom Score (I-PSS),
Overactive Bladder Symptom Score (OABSS), Nocturia Quality of Life (N-QOL), and MOS 36-Item Short-Form Health Survey (SF-36). Higher scores on N-QOL and SF-36
indicate better health, whereas the opposite is true for all other scales and surveys. n values vary between n = 363 and n = 383 due to incomplete data
aPresent is defined as the time of the subject’s initial HAM-net interview
bThe median values for the remaining six SF-36 sub-scores were all within one standard deviation of the national average (40 – 60) and are not shown in this table
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Fig. 3 Age of the HAM-net subjects analyzed in this study. This
graph illustrates the marked delay between age of onset (n = 381)
and age at diagnosis (n = 383) for HAM/TSP patients and shows that
HAM-net subjects have mostly been suffering from the disease for
many years before registering. The most common age of onset was
during the subjects’ 40s, but they were primarily diagnosed in their
50s. Nearly 40 % of HAM-net subjects are currently in their 60s, the
largest HAM-net age demographic
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initial symptoms associated with the onset of HAM/
TSP. Most but not all patients (81.9 %) noticed difficulty
walking, many patients (38.5 %) experienced urinary dys-
function, and a substantial minority (13.9 %) suffered
from lower limb sensory disturbances. Interestingly, this
survey revealed that women were more likely than men
to experience urinary dysfunction as an initial symptom
(43.5 % vs. 24.2 %, respectively, p < 0.001). Moreover, 51
patients (13.4 %) complained of urinary issues before no-
ticing any difficulty walking. The majority of these pa-
tients (43 of 51) were women, who were slightly more
likely than men to exhibit this pattern (15.2 % vs. 8.1 %,
respectively).
Disease progression
Changes in OMDS over time, assessed retrospectively by
conducting a detailed patient history, were used to esti-
mate the rate of disease progression (Fig. 5). A median
of 8 (3–14) years elapsed from the onset of motor symp-
toms to OMDS 5 (requiring unilateral support to walk,
e.g. a cane), 12.5 (7–19) years to OMDS 6 (requiring bi-
lateral support to walk, e.g. a walker), and 18 (10–23)
years to OMDS 9 (unable to walk at all). As illustratedin Fig. 5, the median scores increased steadily until
OMDS 9, at which point they began to decrease again.
We also recorded changes in OMDS over time starting
from disease onset: 9 (3–15) years elapsed from disease
onset to OMDS 5, 14 (7.5–20) years to OMDS 6, and 18
(10–27) years to OMDS 9.
Disease impact
Disability and pain impact the so-called Activities of
Daily Living (ADL), and we assessed this impact using
HAQ-DI. HAM/TSP patients scored a median of 1.1
(0.8–1.6) total (Table 1). Detailed analysis revealed that
they exhibited the most difficulty accomplishing tasks
specifically requiring mobility, such as walking around
(Q8) and climbing stairs (Q9), which were completely
impossible for 34.0 % and 30.4 % of patients, respectively
(Fig. 6). Also frequently impossible were tasks related to
reaching up (Q13, 29.1 %) or down (Q14, 23.3 %) to re-
trieve objects as well as very active endeavors such as
running errands (Q18, 19.9 %) and doing chores (Q20,
18.1 %). The vast majority of patients could complete
tasks related to personal grooming (Q1-2) and hygiene
(Q10-12) as well as getting in and out of bed, chairs,
and the car (Q3, 4, 19), but most experienced some
difficulty performing these tasks independently. On
the other hand, tasks involving mainly hand motions
such as eating (Q5-7) and gripping (Q16-17) could be
performed easily by over 80 % of patients. Total
HAQ-DI score was very well-correlated with OMDS
(ρ = .832, p < 0.001, Fig. 7). Tasks involving heavy use
of the lower limbs (Q3, 8, 9, 13, 19) were well-
correlated with OMDS (ρ = 0.7), whereas the five
tasks involving only hand motions (Q5, 6, 7, 16, 17)
showed very little correlation (ρ < 0.3).
In addition, the SF-36 survey was used to assess the
health-related quality of life of HAM/TSP patients
relative to that of average Japanese citizens, whose
scores were set to 50 with a standard deviation of
10 (Table 1). The average (and median) scores for
six of the eight sub-sections (role-physical, bodily
pain, vitality, social functioning, role-emotional, and
mental health) were within one standard deviation of
normal (between 40 and 60, data not shown). The
score for general health was just barely lower, at a
median of 38.9 (32.5–45.8). The only strikingly impaired
section was physical functioning, where HAM/TSP
patients scored a median of -3.5 with a wide IQR
(−10.7–14.5).
Blood transfusion history
Of the patients enrolled in this study, 73 (19.1 %) had a
history of receiving blood transfusions, 57 of whom
received blood before HTLV-1 screening for blood dona-
tions was implemented in 1986. Of the 16 patients who
Fig. 4 Population map for HAM-net subjects. Map shows the prefectures occupied by HAM/TSP patients enrolled in this study, color-coded according
to the number of subjects (n = 383). Prefectures that are well-known reference points, such as Tokyo, or hot-spots for HAM-net enrollees, such as
Kagoshima, are labeled. Subjects resided in all but six of the 47 prefectures in Japan
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nawa, areas where HTLV-1 is endemic. Those who had
received blood tended to be older than those who had
not: median ages at onset, diagnosis, and present were five
to six years later (Table 3). In addition, although they had
similar, even slightly shorter, disease durations, they expe-
rienced more severe disabilities as indicated by higher
HAQ-DI scores: 1.3 (0.9–1.9) versus 1.0 (0.6–1.6).
Family history of HTLV-1-associated diseases
Several of the enrolled patients had family members
who were also suffering from HAM/TSP. Although
HAM/TSP is estimated to occur in as few as 0.3 % of in-
dividuals infected with HTLV-1 [3], as many as 8.4 % of
enrolled patients reported having first- or second-degree
relatives who also had HAM/TSP. First-degree relativesare parents, siblings, and children; second-degree rela-
tives are aunts, uncles, nieces, nephews, grandparents,
grandchildren, and half-siblings. In addition, 5.7 % of
HAM/TSP patients had a family history of ATLL.
The features of these 32 familial cases were com-
pared with those of the remaining 351 patients
(Table 4). The patients with familial HAM/TSP were
markedly younger, with a median age of onset
13.5 years earlier and age at diagnosis 15 years earlier.
However, there was no evidence that they were diag-
nosed any more quickly; in fact, the median delay be-
tween onset and diagnosis was slightly longer for
familial cases: 6 (2–12) versus 5 (1–12) years. Patients
with familial HAM/TSP had been suffering from the
disease for more extended periods of time than their
non-familial counterparts: 23.5 (14–32) vs. 16 (8–25)
Table 2 Osame Motor Disability Score (OMDS) descriptions and
number of HAM-net subjects (n = 382)
OMDS Description Subjects (Percentage)
0 No walking or running abnormalities 3 (0.8 %)
1 Normal gait but runs slowly 5 (1.3 %)
2 Abnormal gait (stumbling, stiffness) 13 (3.4 %)
3 Unable to run 11 (2.9 %)
4 Needs handrail to climb stairs 47 (12.0 %)
5 Needs a cane (unilateral support) to
walk
130 (34.0 %)
6 Needs bilateral support to walk 65 (17.0 %)
7 Can walk 5-10 m with bilateral support 29 (7.4 %)
8 Can walk 1-5 m with bilateral support 25 (6.5 %)
9 Cannot walk, but able to crawl 19 (5.0 %)
10 Cannot crawl, but able to move using
arms
19 (5.0 %)
11 Cannot move around, but able to turn
over in bed
3 (0.8 %)
12 Cannot turn over in bed 3 (0.8 %)
13 Cannot even move toes 10 (2.6 %)
Data are summarized using the number of subjects (percentage of total
subjects). Scores listed are those at the time of the subject’s initial
HAM-net interview
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not exhibit more severe symptoms: there were no re-
markable differences in OMDS, HAQ-DI scores, urin-
ary and bowel symptom severity, or frequency of
lower limb pain and numbness. Those with a family
history of HAM/TSP were also more likely to have a
family history of ATLL: 15.6 % of patients from the fa-
milial HAM/TSP group had a first- or second-degree
relative with ATLL, whereas only 4.8 % of the non-
familial HAM/TSP group had such a relative.
Discussion
To the author’s knowledge, HAM-net is the first HAM/
TSP patient registry in the world. As an epidemiological
study of HAM/TSP patients, we believe ours is the first
of its size to obtain such a detailed history by communi-
cating directly with each subject. Moreover, a nation-
wide study has not been conducted in Japan since 1990,
when Osame et al. mailed surveys to medical institutions
around the country [16], and after 25 years it was neces-
sary to reevaluate the profile of the Japanese HAM/TSP
patient.
Diagnosing HAM/TSP and monitoring symptoms
Our finding that patients most commonly experience
HAM/TSP onset in their 40s (Fig. 3) is consistent with
the findings of previous studies conducted in Japan [15,
16]. However, we revealed for the first time that there isa long delay between disease onset and diagnosis in
Japan: on average, there was a gap of 7.6 years (median
5, range 0–49, 95 % CI 6.8–8.4 years). For comparison,
the gap was reported to be 5.3 years (median 3, range 0–33,
95 % CI 2.2–5.5 years) in Martinique [19] and 3.8 years
(median 2, range 1–19 years) in the UK [18]. This discrep-
ancy may be partially due to the fact that this national study
includes patients diagnosed in rural areas with limited ac-
cess to professionals familiar with this disease (Fig. 4). All
over the world, many patients must endure a long struggle
with mysterious symptoms before they are finally given a
correct diagnosis, causing psychological strain and perhaps
lowering their chances of managing the disease effectively
[35]. Experts recommend that all spastic paraparesis pa-
tients in or near endemic areas be screened for HTLV-1 to
ameliorate this problem [36, 37].
There is no standard system for monitoring the
symptoms of HAM/TSP patients, and it is difficult to
compare results across studies, especially internationally.
One of the ultimate goals of HAM-net is to establish an
effective system for physicians to track disease progress
and for researchers to compare their findings. To work
towards this goal, we have been gathering data using
several pre-established scales and surveys as well as
questions of our own design.
OMDS has been used for decades to monitor HAM/
TSP patients [25], and in this study it was our primary
means of measuring motor disability (Table 2, Fig. 5).
We also collected similar data using the gait disturbance
subsection of the IPEC-1 scale, named after the Evandro
Chagas Institute of Clinical Research/Instituto de Pes-
quisa Clinica Evandro Chagas (IPEC) in Brazil, which
was recently drafted to tally the presence and severity of
HAM/TSP neurological symptoms including motor,
spasticity, pain, numbness, urinary, and bowel symptoms
[27]. It has been employed in a small clinical study in
the UK [28]. We intend to evaluate the usefulness of
IPEC-1 relative to OMDS in a future study. In this study,
we reported the IPEC-1 gait sub-score and extracted
data on lower limb numbness and pain shown in
Table 1, finding that roughly half of all patients expe-
rienced some degree of lower limb pain and most ex-
perienced numbness.
Our questionnaire revealed that the majority of Japa-
nese HAM/TSP patients require medical intervention to
alleviate their urinary and bowel symptoms. Scores on
the ICIQ-SF, I-PSS, OABSS, and N-QOL scales and sur-
veys also indicated impaired urinary function; however,
the scores were varied, reflecting differences in the na-
ture of each questionnaire. For example, ICIQ-SF and
N-QOL assess impact on quality of life, whereas I-PSS
and OABSS focus on the severity of symptoms. Patients
using unpleasantly aggressive means to treat their symp-
toms, such as catheters, may have eased their symptoms
Fig. 5 Rate of Motor Disability Progression. The table lists the time elapsed to progress to each Osame Motor Disability Score (OMDS) both from
onset of motor symptoms and from disease onset for the HAM/TSP patients enrolled in this study based on retrospective data. The corresponding
graph illustrates the times starting from onset of motor symptoms. The boxes encompass the 25th–75th percentiles, the interquartile range (IQR),
and the bars indicate the minimum and maximum values within 1.5 IQR of the box. Circles represent outliers beyond that range, and stars represent
extreme outliers beyond 3 IQR. Importantly, the medians cease to increase linearly and begin to curve at around OMDS 9, suggesting
variation in progression speeds. In the table, the values for OMDS 5, 6, and 9 are highlighted to emphasize those important time-points:
need for unilateral support, bilateral support, and complete inability to walk, respectively
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ledge, this is the first time scores on ICIQ-SF, I-PSS, or
OABSS have been reported for HAM/TSP patients. N-
QOL was used as an outcome measure in a Japanese
clinical trial for HAM/TSP in 2013 [38]. In future stud-
ies, we plan to use HAM-net data to compare the
usefulness of these methods for monitoring urinary
symptoms in HAM/TSP patients. Our findings demon-
strate that although urinary and bowel symptoms are
less visible, they are highly prevalent and severe in
HAM/TSP patients, and it is critical that they not be
overlooked by physicians during diagnosis, monitoring,
and treatment.
Similar findings in South America have prompted
researchers there to stress the importance of urinary
complaints for the early diagnosis of HAM/TSP [20, 22].
Though they reported that the diagnosis of HAM/TSP
tends to be delayed even longer for patients complaining
first of urinary symptoms [22], we did not observe any
difference in time from onset to diagnosis in this study
(data not shown). We did, however, note that a fraction
of patients experienced urinary symptoms before the
onset of motor symptoms and that women were more
likely than men to experience urinary dysfunction as aninitial symptom. Given this data, doctors in endemic
areas should be made aware that HAM/TSP may
initially present as a problem with urinary function, es-
pecially in women.
HAM/TSP is well known to be two to three times
more common in women than men [10], and as ex-
pected, nearly three-quarters of our subjects were fe-
male. This is thought to be because sexual transmission
of HTLV-1 mainly occurs from male to female [1]; in
addition, there is some evidence that the lifetime risk of
developing HAM/TSP in HTLV-1-positive individuals is
higher in women than men, although it is unclear why
this would be the case [4].
Estimating the rate of disease progression
Measuring changes in OMDS over time is an established
method of estimating the rate of HAM/TSP progression.
In this study, we recorded the number of years that
elapsed between the onset of motor symptoms and pro-
gression to each OMDS reached so far by every patient
who could recall this information (n = 360, Fig. 5). The
results are consistent with the prevailing theory that
while HAM/TSP is generally a slowly progressive dis-
ease, there is significant variation in progression speed,
Fig. 6 Results of the Health Assessment Questionnaire – Disability Index (HAQ-DI). HAM/TSP patients enrolled in HAM-net reported the level of
difficulty they experienced performing each of the 20 HAQ-DI tasks, listed in the figure as Q1-Q20 (n = 382)
Coler-Reilly et al. Orphanet Journal of Rare Diseases  (2016) 11:69 Page 11 of 17including a subset of patients who progress very rapidly.
Figure 5 shows that the IQRs are quite large, illustrating
this wide variation. Moreover, the medians increase
steadily at first but then begin to curve around OMDS 9,
presumably because only the group of patients who pro-
gress at the fastest rate ever reach the highest OMDS
grades. We intend to evaluate progression speed in great
detail in a future study.
Other studies have used similar techniques to evaluate
the speed of motor disability progression in HAM/TSP
patients; however, many of these studies use disease on-
set rather than onset of motor symptoms as a starting
point. Using disease onset yields slightly longer time es-
timates because some patients experience urinary symp-
toms before motor symptoms begin. Therefore, for the
sake of comparison, we also recorded changes in
OMDS over time starting from disease onset: a me-
dian of 9 (3–15) years elapsed from disease onset to
OMDS 5 (requiring unilateral support to walk), 14
(7.5–20) years to OMDS 6 (requiring bilateral support
to walk), and 18 (10 – 27) years to OMDS 9 (unable to
walk at all). Interestingly, Nakagawa et. al. reported in
1995 that it took only 12.4 ± 10.7 years (mean ± standard
deviation) to progress from onset of disease to inability to
walk [15]. Their study was large but only evaluated pa-
tients in Kagoshima prefecture, whereas the present study
includes patients from 41 prefectures. Although there are
no other large-scale studies from Japan on this topic,reports from overseas are also available for comparison. In
the UK, Martin et al. observed that the median times from
disease onset to dependency on a unilateral walking aid
and subsequently a wheelchair were 11 years (95 % confi-
dence interval: 2.8 to 17.30) and 18 years (95 % CI: 14 to
22), respectively [18]. In Martinique, Olindo et al. reported
only 6 years (95 % CI: 5 to 7) from onset to unilateral aid,
13 years (95 % CI: 10 to 17) to bilateral aid, and as long as
21 years (95 % CI: 14 to 28) to wheelchair-dependency
[19]. It should be noted that many of our wheelchair-
bound patients are classified as well below OMDS 9 be-
cause they are still able to stand up from their wheelchairs
and walk short distances with support. Thus, these values
may not be directly comparable. It would benefit HAM/
TSP research if there were an internationally agreed-upon
standard for evaluating motor disability in HAM/TSP
patients.
Assessing disease impact
We assessed the impact of HAM/TSP on ADL using
HAQ-DI (Fig. 6), a scale typically used for chronic
rheumatic conditions such as arthritis [26]. To the au-
thors’ knowledge, this is the first time the HAQ-DI
scores of HAM/TSP patients have been reported. Since
total HAQ-DI score was very well-correlated with
OMDS, we inferred that this score could indeed be a
useful measure for disease severity in HAM/TSP
patients. Moreover, there were many cases where a
Fig. 7 Correlation between motor disability and activities of daily life. Figure shows the correlation between the Osame Motor Disability Score
(OMDS) and the average Health Assessment Questionnaire – Disability Index (HAQ-DI) scores for the HAM/TSP patients enrolled in this study (n = 382).
Circles are sized according to the number of patients at each data point, with the smallest circles indicating a single patient each and the largest
circles indicating 22 patients. The correlation coefficient was ρ = .832
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not OMDS, and vice versa, suggesting that combining
these two measures could allow for more precise track-
ing of disease progression (Fig. 7). Importantly, OMDS
was better correlated with certain HAQ-DI tasks than
with others. Since tasks requiring heavy use of the lower
limbs were particularly strenuous for HAM/TSP pa-
tients, it is of little surprise that those tasks were well-
correlated. By contrast, the five tasks that focused on
hand movements showed very little correlation with





Age at Onset 50
Age at Diagnosis 57
Age (at Presenta) 69
Diagnosis Delay (Time from Onset to Diagnosis)b 5
Disease Duration (Time from Onset to Presenta)c 16
OMDS (Range: 0 – 13) 5.0
HAQ-DI (Range: 0 – 3) 1.3
Data are summarized using the number of subjects (percentage of total subjects) o
shown are Osame Motor Disability Score (OMDS) and Health Assessment Questionn
The values for time-points are given in years, and scale and survey results are repor
aPresent is defined as the time of the subject’s initial HAM-net interview
bTransfusion (+) n = 72, (-) n = 306
cTransfusion (+) n = 72tasks (Q5, 6, 7, 16, 17) if in the future we create a
HAM/TSP-specific ADL scale incorporating HAQ-DI
elements.
We also assessed the impact of HAM/TSP on health-
related quality of life using the SF-36 survey. Scores on
this survey indicated that HAM/TSP severely impairs
physical functioning but does not have a striking effect
on other aspects of quality of life, such as social, emo-
tional, and mental health. This may be due to the
chronic, slowly progressive nature of the disease, which




(n = 307, 80.8 %)
p Value
(79.5 %) 224 (73.0 %) 0.255
(20.5 %) 83 (27.0 %)
(39 – 61) 44 (32 – 55) 0.005
(48 – 67) 52 (41 – 61) 0.004
(58 – 74) 63 (56 – 68) 0.001
(1 – 12) 5 (1 – 12) 0.730
(8 – 23) 17 (9 – 26) 0.403
(5.0 – 7.5) 5.0 (5.0 – 7.0) 0.212
(0.9 – 1.9) 1.0 (0.6 – 1.6) 0.022
r the median (interquartile range). The full names of the scales and surveys
aire – Disability Index (HAQ-DI). Higher scores indicate more severe disability.
ted as scores
Table 4 Variation in clinical attributes with family history of HAM/TSP (n = 383)
Attribute Familial HAM/TSP
(n = 32, 8.4 %)
Non-Familial HAM/TSP
(n = 351, 91.6 %)
p Value
Sex: Female 19 (59.4 %) 265 (75.5 %) .046
Male 13 (40.6 %) 86 (24.5 %)
History of ATLLa: Yes 5 (15.6 %) 17 (4.8 %) .012
History of Blood Transfusion: Yes (anytime) 2 (6.3 %) 71 (20.4 %) .052
Yes, before 1986 2 (6.3 %) 55 (15.8 %) .147
Age at Onset 32.5 (25 – 45) 46 (34 – 56) .000
Age at Diagnosis 40 (30 – 54) 55 (44 – 62) .000
Age (at Presentb) 58 (52 – 66) 64 (56 – 70) .018
Diagnosis Delay (Time from Onset to Diagnosis) 6 (2 – 12) 5 (1 – 12) .765
Disease Duration (Time from Onset to Presentb) 23.5 (14 – 32) 16 (8 – 25) .002
OMDS (Range: 0 – 13) 5.0 (5.0 – 8.0) 5.0 (5.0 – 7.0) .481
HAQ-DI (Range: 0 – 3) 0.9 (0.5 – 1.9) 1.1 (0.8 – 1.6) .677
Data are summarized using the number of subjects (percentage of total subjects) or the median (interquartile range). The full names of the scales and surveys
shown are Osame Motor Disability Score (OMDS) and Health Assessment Questionnaire – Disability Index (HAQ-DI). The values for time-points are given in years,
and scale and survey results are reported as scores. n values vary between n = 379 and n = 383 due to incomplete data
aHistory of ATLL indicates the subject has a first- or second-degree relative with adult T-cell leukemia/lymphoma (ATLL)
bPresent is defined as the time of the subject’s initial HAM-net interview
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vidual variation, and it is likely that patients in the ad-
vanced stages of HAM/TSP suffer from more quality of
life deficits than the average patient. We intend to per-
form further analysis in future studies, determining what
factors affect quality of life most and which SF-36 sub-
sections are most useful for monitoring HAM/TSP
patients.
Importance of blood transfusion history
HTLV-1 can be transmitted by blood transfusion, but
this risk has been considered relatively negligible since
1986, when nationwide screening of blood donors for
HTLV-1 was implemented in Japan [16, 39]. As illus-
trated by the distribution of HAM-net subjects shown in
Fig. 4, HTLV-1-associated disease has spread all
throughout Japan; however, our data indicates that blood
donor screenings have been effectively limiting the
spread via contaminated blood since 1986. In 1990,
Osame et al. found that 23.8 % of HAM/TSP patients
had a history of blood transfusion but that the number
of patients developing transfusion-associated HAM/TSP
had already dropped precipitously since 1986 [16]. For
comparison, they conducted surveys among random
Kagoshima prefecture residents and hospitalized neuro-
logical patients, and they found that the frequencies of
blood transfusion history in these control populations
were 3 and 5 %, respectively, when age- and sex-
matched to the HAM/TSP patient group. If the 57 pa-
tients who received blood before 1986 are excluded from
the analysis, only 5.0 % (16/323) of our patients had a
history of blood transfusion. Thus, although these dataare not directly comparable, it is clearly possible that
some or all of these transfusions were merely coinciden-
tal. Moreover, 10 of those 16 patients who received
blood post-1986 originated from HTLV-1-endemic areas
in southern Japan (Kyushu and Okinawa), where the risk
of sexual and vertical transmission is relatively high.
Therefore, we have inferred that the 1986 measures have
likely been effectively limiting the spread of HTLV-1 via
blood transfusion.
Patients with a history of blood transfusion (n = 73), as
compared to those without (n = 307), exhibited more se-
vere symptoms (Table 3). This may be due to an elevated
immune response following blood transfusion [40]. To the
authors’ knowledge, this is the first time such a trend has
been demonstrated. In fact, previous studies have reported
that history of blood transfusion does not impact disease
severity or progression speed [15, 17]. Those studies did
however agree with our result that transfusion recipients
were older than their non-recipient counterparts, which
may also have contributed to their relatively poor out-
comes [15, 22]. In fact, since HTLV-1 screening for blood
transfusions was implemented in 1986, it could be argued
that most patients who were infected by contaminated
blood must be old enough to have received a transfusion
at least 30 years ago. These patients might then suffer
from more severe symptoms merely due to their age, not
due to the mode of transmission. It may be possible to do
an age-matched comparison in the future.
Importance of family history
Our finding that 8.4 % of our subjects had a first- or
second-degree relative with HAM/TSP is consistent with
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HAM/TSP patients had a sibling, parent, or grandparent
with HAM/TSP [16]. This is considered a relatively high
rate of familial outbreak given that only 0.3 % of HTLV-
1 carriers are estimated to develop HAM/TSP in their
lifetimes [3]. We also evaluated the attributes of patients
with a family history (Table 4), and our results agreed
with those of previous studies, which showed that famil-
ial cases of HAM/TSP present with a younger age of on-
set and a slower rate of progression compared to
sporadic cases [25, 41]. Importantly, this study revealed
that those with a family history of HAM/TSP are also
more likely to have a family history of ATLL. To the au-
thors’ knowledge, this is the first time such a trend has
been reported.
The relatively high rates of disease outbreak within
families may indicate that genetic risk factors play a
role in determining whether an HTLV-1 infection will
develop into a serious illness. Indeed, genetic traits,
namely certain HLA alleles, have been reported to
confer increased or decreased susceptibility to HAM/
TSP [42, 43] or ATLL [44], albeit confined to specific
ethnic groups [45, 46]. We know of no genetic markers re-
ported to affect susceptibility to both diseases.
An alternative line of reasoning involves considering
that family history of HTLV-1-associated diseases im-
plies vertical transmission of HTLV-1, i.e. mother-to-
child, mostly through breastfeeding [47]. Supporting evi-
dence for this reasoning includes that early infection
would explain the comparatively younger ages of onset
in the patients with familial HAM/TSP. It has been
established that ATLL is linked to HTLV-1 infection in
early childhood via vertical transmission, which is said to
allow time for ATLL to develop after its typical latency
period of multiple decades [48, 49]. Unlike ATLL,
HAM/TSP is more commonly associated with HTLV-1
infection acquired during adulthood, either via sexual
transmission or blood transfusion [49]; however, vertical
transmission of HTLV-1 can also lead to HAM/TSP [50,
51]. Bartholomew et al. reported that 97 % of the
mothers of their ATLL patients and 33 % of the mothers
of their HAM/TSP patients were seropositive for HTLV-
1 [51]. Thus, given the strong association between verti-
cal transmission and ATLL, and assuming that cases of
familial HAM/TSP are largely cases of vertical transmis-
sion, it logically follows that a high percentage of these
patients would have a family history of ATLL in agree-
ment with our results.
Similarly, the relatively high percentage of patients
with a family history of HAM/TSP (8.4 %) compared to
the rate of HAM/TSP in the general HTLV-1-infected
population (0.3 %) could be explained if vertical trans-
mission of HTLV-1 conferred greater susceptibility to
HAM/TSP than sexual transmission, which is the mostcommon transmission route [49]. Much about HAM/
TSP pathogenesis is still unknown, and it is possible that
the opportunity for the infection to develop over several
decades could increase the likelihood of developing
HAM/TSP as well as ATLL. The latency period for
HAM/TSP can also be a long as multiple decades [50],
which suggests that early infection would increase the
likelihood of developing the disease within the carrier’s
lifetime. This theory is only speculation, and there is no
evidence to directly support the claim that vertical trans-
mission increases susceptibility to HAM/TSP. However,
indirect evidence abounds. Studies have shown that
HTLV-1 carriers with a family history of HAM/TSP or
ATLL have significantly higher proviral loads [52, 53].
Moreover, animal experiments have directly shown that
vertical transmission (specifically oral transmission) of
HTLV-1 results in elevated proviral load [54, 55]. Finally,
it is well established that high proviral load is associated
with the development of HAM/TSP [56]. Thus, it is rea-
sonable to speculate that vertical transmission of HTLV-
1 may result in young HTLV-1 carriers with compara-
tively high proviral loads who are more likely to develop
HAM/TSP than those infected sexually during adult-
hood. Those who develop HAM/TSP would belong in
our familial HAM/TSP patient group and likely present
as younger and with milder inflammatory symptoms ei-
ther due to their youth or greater tolerance for the
virus afforded by vertical transmission [57]; this pre-
diction is consistent with our results. Thus, the au-
thors propose that a future study should be carried
out to assess whether vertical transmission in infancy
confers a greater susceptibility to HAM/TSP than
sexual transmission in adulthood, as is the case for
ATLL.
Limitations of this study
As a retrospective study based largely on patient recol-
lections, our findings were vulnerable to recall error.
Subjects may have mistakenly reported inaccurate infor-
mation. Many subjects were elderly and did not have ac-
cess to past medical records for reference. In future
HAM-net studies, we will be able to rely more heavily
on prospective analysis using data from the yearly
follow-up interviews.
As with any registry, there is also the problem of re-
cruitment bias. In order to recruit a sample representa-
tive of the general population in Japan, we sent
information to all board-certified neurologists in the
country, and patients were recruited from 41 of the 47
prefectures (Fig. 4). Still, a disproportionate number of
patients were recruited from Kanagawa prefecture, pre-
sumably because our own HAM/TSP outpatient clinic
recruits more effectively. It is also possible that many
who live in rural areas did not seek medical advice for
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thus did not have the chance to learn about HAM-net,
reducing our registry’s coverage. Another issue is that
patients with a family history may have been more likely
to consult a neurologist at the first sign of symptoms
and thus more likely to join HAM-net. However, our
data indicates that those with familial HAM/TSP were
not diagnosed any more quickly than those without a
family history (Table 4).
It is impossible to calculate the percentage of Japanese
HAM/TSP patients who are enrolled in HAM-net, i.e.
the coverage of the registry, because there is no official
estimate of the number of HAM/TSP patients in Japan.
In 1990, Osame et al. conducted a national survey and
reported that there were at least 589 cases of HAM/TSP
in Japan, while acknowledging that this was almost cer-
tainly a dramatic underestimate [16]. If it is true that
there are 1.08 million people infected with HTLV-1 in
Japan [2] with a 0.25 % lifetime incidence of HAM/TSP
[3], there would necessarily be fewer than 2700 Japanese
HAM/TSP patients. Considering these data as well as
unofficial reports from colleagues, the authors speculate
that there may be roughly 2000–2500 individuals suffer-
ing from HAM/TSP in Japan. With 383 subjects, this
study would have thus enrolled about 15–20 % of the
target population.
Future directions
As mentioned, we plan to address certain topics in
greater detail in future studies. To learn more about the
variation in the rate of HAM/TSP progression, we in-
tend to divide patients into groups based on progression
speed and compare attributes between groups. We also
plan to analyze which scales and surveys best reflect dif-
ferences in the symptoms of HAM/TSP patients and
eventually establish an effective monitoring method. In
addition, we will be able to conduct prospective studies
using data from yearly follow-up interviews; for example,
we will be able to monitor the effects of treatments such
as oral steroids over time. Finally, not only are we con-
tinuing yearly follow-up interviews for the current
HAM-net subjects, but we are still accepting applica-
tions for new enrollees, and we expect the reach of
HAM-net to expand over time. Since the data for this
study was obtained and analyzed last year, we have
already enrolled more patients, bringing our total up to
467 registered HAM-net subjects as of March 2016.
Conclusions
By establishing a registration system for HAM/TSP pa-
tients, we have created an invaluable resource for epi-
demiological analysis. We were able to determine the
demographics of HAM/TSP patients in Japan, including
gender, age, and geographic location, giving us a betterunderstanding of our patient population. Analysis of
symptoms, such as motor, urinary, bowel, and sensory
dysfunction, as well as disease impact, gave us new in-
sights into the patient experience. Our examination of
the course of the disease and the factors that influence it
is expected to provide physicians with the means to
make more accurate prognoses based on age, history of
blood transfusion, and family history of HTLV-1-associated
diseases. Finally, as is often the case with epidemiological
studies, we found patterns that should inspire researchers
to uncover new information about the pathogenesis and
treatment of this disease, namely investigating if and
how the mode of HTLV-1 transmission affects patient
prognosis.
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